Ed Groleau

Ed Groleau has over 30 years of experience in the Pharmaceutical industry. The first 15 years were spent in a variety of laboratories for small molecule drug development.  He started out developing and validating analytical testing methods at Merrell Dow Pharmaceuticals and Eli Lilly.  He became Lilly’s primary X-ray powder diffraction expert and was a founding member of the company’s Physical Characterization group that established the optimal salt form for compounds in development.  Being responsible for all XRD, XRF, and thermometric techniques, Ed was also part of Lilly’s internal forensics team conducting investigations for internal manufacturing issues and external litigations.  After 7 years of physical characterization Ed moved to the chemical characterization group where he helped determine the structures of degradation products using NMR.

Ed moved to Lilly’s Clinical Trial Supplies group in 2003 starting in the group responsible for packaging and labeling of IP.  His responsibilities increased as the department changed over the years to include all aspects of CT supplies from planning to distribution. In 2011 he became part of a small, highly integrated CM&C team responsible for overseeing the development of compounds from discovery through proof-of-concept stage.  On this team Ed developed the procedures and processes required to conduct all aspects of the supplies for clinical trials from manufacturing through reconciliation.

In 2016 Ed moved to Elanco, Lilly’s animal health division, where he established a global clinical trial supplies group for developing companion and food animal projects.  Ed’s career at Lilly/Elanco ended in 2017 when he took advantage of an early retirement program the company offered.  Not ready to actually retire, Ed has joined a growing supply chain group at PCI where he continues to provide his experience and expertise to other companies in need of the service.